Capivasertib治疗AKT1 E17K突变肿瘤的NCI-MATCH子方案EAY131-Y非随机试验
该非随机试验纳入35例经标准治疗进展的AKT1 E17K突变转移性肿瘤患者,接受pan-AKT抑制剂capivasertib治疗。客观缓解率(ORR)为28.6%(95%CI 15%-46%),包括1例完全缓解,6个月无进展生存(PFS)率为50%(95%CI 35%-71%)。31%患者因不良事件停药,常见3级不良事件为高血糖(23%)和皮疹(11%)。
要点
- Capivasertib在AKT1 E17K突变肿瘤中ORR达28.6%,含1例完全缓解。
- 6个月PFS率50%,中位随访28.4个月。
- 31%患者因不良事件停药,需关注高血糖和皮疹。
核心结论
- Capivasertib在经治的AKT1 E17K突变肿瘤患者中显示出有临床意义的客观缓解率,包括1例完全缓解。
- 单药capivasertib在难治性恶性肿瘤(包括罕见肿瘤)中表现出临床活性。
研究设计与样本
- NCI-MATCH子方案EAY131-Y非随机试验,2016年7月13日至2017年8月10日入组。
- 纳入35例可评估的成人AKT1 E17K突变转移性肿瘤患者,标准治疗进展后接受capivasertib治疗。
- Capivasertib剂量为480 mg口服每日两次,每周服药4天停3天,28天为一周期;若继续内分泌治疗则剂量为400 mg。
- 主要终点为ORR(RECIST 1.1),次要终点包括PFS、6个月PFS、总生存和安全性。
主要发现
- ORR为28.6%(95%CI 15%-46%)。
- 1例子宫内膜样腺癌患者达完全缓解,持续治疗35.6个月。
- 9例确认部分缓解:7例激素受体阳性/ERBB2阴性乳腺癌,1例子宫平滑肌肉瘤,1例涎腺嗜酸细胞癌(持续治疗28.8个月)。
- 16例(46%)最佳疗效为疾病稳定,2例(6%)疾病进展,7例(20%)不可评估。
- 中位随访28.4个月,6个月PFS率为50%(95%CI 35%-71%)。
临床怎么用
- 对于标准治疗进展的AKT1 E17K突变转移性肿瘤患者,可考虑使用capivasertib。
- 治疗期间需监测高血糖和皮疹等不良事件,必要时调整剂量或停药。
局限性
- 非随机试验,样本量较小(35例可评估)。
- 缺乏对照组,无法直接比较capivasertib与其他治疗的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial, agents targeting genetic tumor abnormalities are administered to patients. In the NCI-MATCH subprotocol EAY131-Y trial, patients with an AKT1 E17K-mutated metastatic tumor received the pan-AKT inhibitor capivasertib. OBJECTIVE: To assess the objective response rate (ORR) of capivasertib in patients with an AKT1 E17K-mutated tumor. DESIGN, SETTING, AND PARTICIPANTS: Between July 13, 2016, and August 10, 2017, patients in the NCI-MATCH trial were enrolled and assigned to the subprotocol EAY131-Y nonrandomized trial. Patients included adults with an AKT1 E17K-mutated metastatic tumor that had progressed with standard treatment, and these patients were assigned to receive capivasertib. Tumor assessments were repeated every 2 cycles. Data analysis of this evaluable population was performed from November 8, 2019, to March 12, 2020. INTERVENTIONS: The study treatment was capivasertib, 480 mg, orally twice daily for 4 days on and 3 days off weekly in 28-day cycles until disease progression or unacceptable toxic effect. If patients continued hormone therapy for metastatic breast cancer, the capivasertib dose was 400 mg. MAIN OUTCOMES AND MEASURES: The primary end point was the ORR (ie, complete response [CR] and partial response) according to the Response Evaluation Criteria in Solid Tumors criteria, version 1.1. Secondary end points included progression-free survival (PFS), 6-month PFS, overall survival, and safety. RESULTS: In total, 35 evaluable and analyzable patients were included, of whom 30 were women (86%), and the median (range) age was 61 (32-73) years. The most prevalent cancers were breast (18 [51%]), including 15 patients with hormone receptor (HR)-positive/ERBB2-negative and 3 with triple-negative disease, and gynecologic (11 [31%]) cancers. The ORR rate was 28.6% (95% CI, 15%-46%). One patient with endometrioid endometrial adenocarcinoma achieved a CR and remained on therapy at 35.6 months. Patients with confirmed partial response had the following tumor types: 7 had HR-positive/ERBB2-negative breast cancer, 1 had uterine leiomyosarcoma, and 1 had oncocytic parotid gland carcinoma and continued receiving treatment at 28.8 months. Sixteen patients (46%) had stable disease as the best response, 2 (6%) had progressive disease, and 7 (20%) were not evaluable. With a median follow-up of 28.4 months, the overall 6-month PFS rate was 50% (95% CI, 35%-71%). Capivasertib was discontinued because of adverse events in 11 of 35 patients (31%). Grade 3 treatment-related adverse events included hyperglycemia (8 [23%]) and rash (4 [11%]). One grade 4 hyperglycemic adverse event was reported. CONCLUSIONS AND RELEVANCE: This nonrandomized trial found that, in patients with an AKT1 E17K-mutated tumor treated with capivasertib, a clinically significant ORR was achieved, including 1 CR. Clinically meaningful activity with single-agent capivasertib was demonstrated in refractory malignant neoplasms, including rare cancers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00700882.
引用
- Kalinsky K, Hong F, McCourt CK, et al. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. JAMA Oncol. 2021. PMID: 33377972. doi:10.1001/jamaoncol.2020.6741
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。